Intranasal corticosteroids for non-allergic rhinitis

Segboer, Christine; Gevorgyan, Artur; Avdeeva, Klementina; Chusakul, Supinda; Kanjanaumporn, Jesada; Aeumjaturapat, Songklot; Reeskamp, Laurens F.; Snidvongs, Kornkiat; Fokkens, Wytske J.

doi:10.1002/14651858.cd010592.pub2

Cited by 26 publications

(22 citation statements)

References 84 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…521,522 A 2019 Cochrane review concluded that it is unclear whether INCS, compared with placebo, reduce patientreported disease severity in patients with NAR. 523 Topical INAH, azelastine and olopatadine, have been shown to reduce symptoms of NAR. 524 Two 3-week multicenter, randomized, DBPC, parallel-group clinical trials (n 5 223 study 1; n 5 203 study 2) conducted in patients with VMR revealed numerical improvements in total VMR symptom score for azelastine compared with placebo from baseline (mean numerical change 1.54 vs 84, P 5 .002 in study 1; mean numerical change 1.54 vs 0.88, P 5 .005 in study 2).…”

Section: Pharmacotherapy For Narmentioning

confidence: 99%

Rhinitis 2020: A practice parameter update

Parameters

Contributors

2020

Journal of Allergy and Clinical Immunology

229

189

View full text Add to dashboard Cite

Section: Pharmacotherapy For Narmentioning

confidence: 99%

Rhinitis 2020: A practice parameter update

Parameters

Contributors

2020

Journal of Allergy and Clinical Immunology

229

189

View full text Add to dashboard Cite

“…Intranasal corticosteroids for non‐allergic rhinitis: By Segboer C, Gevorgyan A, Avdeeva K, Chusakul S, Kanjanaumporn J, Aeumjaturapat S, Reeskamp L, Snidvongs K, Fokkens W 4 …”

Section: Cochrane Abstractmentioning

confidence: 99%

Cochrane corner: Intranasal corticosteroids for non‐allergic rhinitis

Gregory

Grewal

2022

Clin Experimental Allergy

View full text Add to dashboard Cite

Chronic rhinitis, manifesting as sneezing, nasal itching, congestion and rhinorrhoea, is a global health problem affecting up to 40% of the population. 1 A quarter to a half of patients with chronic rhinitis have non-allergic rhinitis (NAR), defined as persistent symptoms of rhinitis with no obvious allergic, infectious or anatomical cause. 2,3 The treatment options include avoidance of known triggers, medication and surgery. A number of medications are used to treat NAR; however, the role and benefit of individual medications in this multifaceted disease are poorly understood.This review focuses on the use of intranasal corticosteroids for treating NAR and compares it to other medications or no treatment.

show abstract

“…68,108 In respect of non-allergic rhinitis, a recent Cochrane review showed that INC use has only short-term beneficial effects on symptom severity, potentially depending on individual phenotypic characteristics. 109 INCs have a rapid onset of action, while the newer preparations such as mometasone furoate, fluticasone furoate (FP), and fluticasone propionate present negligible systemic absorption; thus, they are mostly suitable for children. 110 An as-needed use can be an efficacious alternative for children with seasonal AR symptoms, especially in families with safety concerns on daily CS use, in order to increase adherence.…”

Section: Intranasal Corticosteroids (Incs)mentioning

confidence: 99%

New concepts in pediatric rhinitis

Papadopoulos

Aggelides

Stamataki

et al. 2021

Pediatric Allergy Immunology

View full text Add to dashboard Cite

Rhinitis-and especially allergic rhinitis (AR)-remains the most frequent hypersensitivity condition, affecting up to a quarter of the population and impacting the quality of life of individual patients and the health economy. Data, especially with respect to underlying pathophysiologic mechanisms, mainly derive from studies on adults and are subsequently extrapolated to the pediatric population. Therapeutic algorithms for children with rhinitis are long based on the same principles as in adults. We explore and describe novel aspects of rhinitis, ranging from mechanisms to disease classification, phenotypes, diagnostic and monitoring tools, and the use of treatments, with a focus on the traits of pediatric age groups.

show abstract

Intranasal corticosteroids for non-allergic rhinitis

Cited by 26 publications

References 84 publications

Rhinitis 2020: A practice parameter update

Rhinitis 2020: A practice parameter update

Cochrane corner: Intranasal corticosteroids for non‐allergic rhinitis

New concepts in pediatric rhinitis

Contact Info

Product

Resources

About